Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report

INTRODUCTION: In mid-February, the nationwide immunization plan for the prevention of coronavirus disease 2019 (COVID-19) started in Japan (at first primarily focused on health professionals) using an mRNA-based vaccine (Pfizer/BioNTech). During the phase-in period from February to March, attention...

Descripción completa

Detalles Bibliográficos
Autores principales: Iguchi, Toyotaka, Umeda, Hikari, Kojima, Michie, Kanno, Yuri, Tanaka, Yuta, Kinoshita, Natsumi, Sato, Daisaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335977/
https://www.ncbi.nlm.nih.gov/pubmed/34347278
http://dx.doi.org/10.1007/s40264-021-01104-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335977/
https://www.ncbi.nlm.nih.gov/pubmed/34347278
http://dx.doi.org/10.1007/s40264-021-01104-9

Ejemplares similares